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Genotype imputation has become a standard technique prior genome-wide association studies 20 (GWASs). For common and low-frequency variants, genotype imputation can be performed 21 sufficiently accurately with publicly available and ethnically heterogeneous imputation reference 22 panels like 1000 Genomes Project (1000G) and Haplotype Reference Consortium. However, the 23 imputation of rare variants has been shown to be significantly more accurate when ethnically matched 24 reference panel is used. Even more, greater genetic similarity between reference panel and target 25 samples facilitates the detection of rare (or even population-specific) causal variants. Notwithstanding, 26 the genome-wide downstream consequences and differences of using ethnically mixed and matched 27 reference panels have not been yet comprehensively explored. 28 We determined and quantified these differences by performing several comparative evaluations of the 29 discovery-driven analysis scenarios. A variant-wise GWAS was performed on seven complex diseases 30 and body mass index by using genome-wide genotype data of ~37,000 Estonians imputed with 31 ethnically mixed 1000G and ethnically matched imputation reference panels. Although several 32 previously reported common (minor allele frequency; MAF > 5%) variant associations were replicated 33 in both imputed datasets, no major differences were observed among the genome-wide significant 34 findings or in the fine-mapping effort. In the analysis of rare (MAF < 1%) coding variants, 46 35 significantly associated genes were identified in the ethnically matched imputed data as compared to 36 four genes in the 1000G panel based imputed data. All resulting genes were consequently studied in 37 the UK Biobank data. 38
These associated genes provide an example of how rare variants can be efficiently analysed to 39 discover novel, potentially functional genetic variants in relevant phenotypes. Furthermore, our work 40 serves as proof of a cost-efficient study design, demonstrating that the usage of ethnically matched 41 imputation reference panels can enable improved imputation of rare variants, facilitating novel high-42 confidence findings in rare variant GWAS scans. 43
Introduction demonstrated the utility of ethnically matched datasets for the discovery of disease or trait-associated 80 rare variants [18] [19] [20] [21] [22] [23] [24] [25] . 81
Imputed datasets based on ethnically matched reference panels are considered to be powerful tools to 82 discover previously unidentified rare variants. However, the typical approaches for testing associations 83 of genetic variants with phenotypes based on simple regression models, and are underpowered for rare 84 variants in most studies due to their low frequencies and large numbers [26] . To overcome these 85 issues, different methods have been proposed to increase statistical power in rare variant association 86 studies, typically by combining information across multiple rare variants within a specific genomic 87 region or functional unit (e.g. gene) [27] [28] [29] . Often these methods focus on certain categories of 88 variation (e.g. missense or loss-of-function (LoF) variants) [30] , and have been applied successfully in 89 several studies [31] [32] [33] . Therefore, gene-based tests allow to capture the joint contribution of multiple 90 rare variants, improve power and enable to identify novel disease associated genes encompassing 91 putatively functional variants [34] [35] [36] [37] . 92
In the current study, we impute 51,886 chip-typed Estonians with both ethnically matched Estonian-93 Finnish (EstFin) and ethnically mixed 1000G imputation reference panels (IRPs) to determine and 94 quantify the differences in analysis results of eight complex traits. In particular, we evaluate two 95 analysis scenarios: 1) a variant-wise GWAS; 2) a gene-wise analysis to determine the joint 96 contribution of rare (MAF < 1%) nonsynonymous 97 in the UK Biobank data (Fig 1) .
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Single variant analysis 108
We analyzed the associations between imputed variants and eight complex traits: body mass index and 109 seven complex diseases of major public health importance [38] -bipolar disorder (BD), coronary 110 artery disease (CAD), Crohn's disease (CD), hypertension (HT), rheumatoid arthritis (RA), type 1 111 diabetes (T1D), and type 2 diabetes (T2D) (S2 Table) . Analyses were conducted separately in both 112 imputed datasets. Results of variant-wise GWA studies are summarized in Table 1 respectively. In both datasets we discovered eleven identical loci and three IRP-specific associations, 115 all of which have been previously reported [1] (S3 Table) . Autoimmune diseases RA and T1D 116 demonstrated common variant associations in the HLA-region, BMI and T2D revealed long 117 established association with FTO gene (Fig 2) . Although lead variants did not overlap (except 118 rs11102694 and rs9273363 with T1D), top hits from both datasets were in close proximity and in high 119 linkage disequilibrium (S4 Table and S4 Fig) . IRP-specific associations included BCL2L15 association with T1D in case of the EstFin panel based 121 imputation, whereas an intergenic locus at chromosome 6p12.3 was associated with BMI and TLE1 122 locus with T2D in the 1000G-based imputed data only, although the lowest P values of another IRP-123 based imputed data were close to the genome-wide significance level (S4 Table and (BMI -body mass index, CADcoronary artery disease, RA -rheumatoid arthritis, T1D -type 1 diabetes, T2D -type 2 diabetes) . Analyses are conducted separately in the EstFin-based and the 1000G-based imputed datasets. The genome-wide significance threshold after correction for multiple testing is P < 6.25 × 10 −9 . For each locus, associated gene containing variant with the lowest P value, is reported. In the last two columns, results of fine-mapping analysis are shown with the numbers of putative causal variants per genomic region. (1) Genome-wide significant (P < 3.27 × 10 −8 , 10-fold enrichment in Estonians) variants detected in MAFenriched analysis in comparison of 503 European individuals from the 1000G phase 3 data.
Associated gene
Number To identify the likely causal variant at each locus, we performed fine-mapping analysis in all 125 significant genomic regions discovered in genome-wide association scan. All but three (BMI at 126 2p25.3, RA and T1D at the HLA-region) significant regions demonstrated only one likely causal 127 variant (Table 1) . We also tested variants having allele frequency enrichment in Estonians as com-128 pared to the 503 European individuals from the 1000G data. Genome-wide significant (P < 3.27 × 10 −8
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for 10-fold enrichment) variants were detected for BMI at 1q25.2, 2p25.3, and 18q21.32 loci and for 130 RA and T1D in the HLA-region in both imputed datasets (Table 1) . 131
In conclusion, single variant association analyses did not indicate major differences in results based on 132 these data imputed with ethnically matched and mixed IRPs. evidence for an association between T2D and alleles of the FTO -11 ). The same SNV shows a significant association in the data , but the lowest P value is at rs1421085 (P = 7. parative results of gene-based analysis are presented in Figure  146 associated genes were implicated 147 involved in gene-wise analysis (S5 Table) 148 significant gene-trait associations 149 relied on four or more NS/LoF variants and 150 by multiple variants (P < 0.05) for 22/52 tests 151 analysis of NS variants we identify 1000G-based data. In the EstFinsubstitutions, whereas none of the 1000G IRP. Table) . We determined that the large majority (45 out of 52) s relied on two or three NS/LoF variants. Seven out of 52 associations relied on four or more NS/LoF variants and the signal of joint contribution of rare variants < 0.05) for 22/52 tests (S5 Table) .
Gene-based analysis
based analysis on bipolar disorder. The top panel shows the gene results using the EstFin-based imputed data, while the bottom part shows results for the Blue dots represent tested genes including NS variants and variants. Dashed lines indicate significance levels after correction for multiple testing: P −6 for LoF variants (orange). Red symbols denote significant genes. In the variants we identify six genes based on the EstFin IRP data and one -based imputed data we detect a single gene-trait association of LoF of the significant associations is observed in the data based on e s, we detected 38 significant gene-trait puted data and four in the 1000G panel based we detected 10 genes including rare LoF based imputation (Table 2) The top panel shows the gene-based based imputed data, while the bottom part shows results for the Blue dots represent tested genes including NS variants and orange squares LoF P < 4.83 × 10 −7 for NS Red symbols denote significant genes. In the significant gene in the trait association of LoF bserved in the data based on ethnically mixed Table 2 . Overview of significant gene-based associations. Genes with at least two confidently imputed (INFO > 0.8) rare (MAF < 1%) nonsynonymous (NS) and loss-offunction (LoF) variants are tested for association with complex traits (BMI -body mass index, BD -bipolar disorder, RA -rheumatoid arthritis, T1D -type 1 diabetes, T2D -type 2 diabetes). Analyses are performed separately in the EstFin-based and the 1000G-based imputed datasets. Multiple testing corrected significance levels are applied based on the number of genes tested in both datasets: P NS < 4.83 × 10 −7 for genes containing NS variants and P LoF < 9.40 × 10 −6 for genes containing LoF variants. First, the results of genebased analysis in 36,716 Estonian Biobank (EBB) individuals are presented. Next, the gene-trait associations are validated in 405,379 UK Biobank (UKBB) individuals. Finally, for each significant gene-trait result detected in the EBB data, variant-trait association with the smallest P value from the UKBB single variant GWAS is provided. 
Validation of gene-based analysis 152
We first selected 52 significant gene-trait associations from the gene-wise analysis and repeated the 153 gene-based tests using 405,379 individuals from the UK Biobank [39, 40] . The strongest gene-trait 154 associations were detected with CD in GRWD1 (P = 0.022) and ZNF92 (P = 0.046) genes, but neither 155 of these were significant after correcting for multiple testing (Table 2) . 156
Secondly, we used variant-wise GWAS results of the UK Biobank in 361,194 individuals [41] . and HLA-G as well as few other loci are discussed in S1 Appendix. Relevant GWAS Catalog entries 166 related to significant findings from gene-based analysis are presented in S6 Table. 167
Gene-based analysis of rare variants demonstrated that our ethnically matched panel outperformed the 168 1000G-based imputation, provided 10-fold increase in tested genes and significant findings. 169
Validation indicated that most of the significantly associated genes were previously known, but there 170 were some which turned out to be worthwhile novel findings. 171
Discussion
Over the past few years, ethnically matched imputation reference panels have been implemented in 173 favour of widely used cosmopolitan 1000G and HRC panels. The former mentioned panels have 174 Table) . The difference increases with the decrease of MAF, because 185 of the insufficient representation of rare variants in the 1000G IRP. We observed that single variant 186 GWAS identified a similar number of genome-wide significant findings in these two imputed datasets 187 and we did not detect any major differences in fine-mapping of these loci. At the same time, it should 188 be taken into consideration that in the current analyses we rely on a relatively small number of disease 189 correction. For gene-trait associations detected in the EBB data, we were not able to validate 6 (out of 211 42) and 9 (out of 10) genes containing NS and LoF variants, respectively. This was accounted for the 212 UKBB data containing less than two NS and LoF variants within these genes ( Table 2) . A likely 213 explanation is that the ethnically matched panel captures a significantly larger number of such rare 214 variants which are not well-captured through the imputation with more heterogeneous reference 215
panels. Therefore we argue that failing to validate most of the gene-based analysis results in the UK 216
Biobank data can be due to the population-specific nature of the rare variant findings. 217
Nevertheless, some of the associations were validated by matching the observed significant genes with 218 the variants located in the same gene regions in the UKBB single variant association analysis, as well 219 as many of the genes detected by us were associated with relevant traits in literature (S1 Appendix). 220
We hypothesize about a causative role for LPP variants conferring susceptibility to T1D -an 221 assumption being initially rejected in a study involving both celiac disease and T1D patients [42] . 222 Pleiotropic effects have been reported for LPP in association studies involving diverse autoimmune di-223 seases where shared susceptibility factors outside the HLA-region are widely recognized. In addition, 224 LPP mRNA and protein are expressed in multiple tissues, including islets of Langerhans and pancreas, 225
and LPP gene is relatively intolerant of LoF variation (ExAC pLI = 0.58) [43] . 226
In conclusion, we observed that analysis of rare variants outperforms the ethnically matched 227 imputation reference panel compared to multi-ethnic panels. The use of an ethnically matched panel 228 ensures a far better imputation quality for rare variation and allows capturing more population-specific 229 variants, enabling more efficient discovery of disease-associated genes. 230
Materials and methods
231
Study cohorts
232
Estonian Biobank. The Estonian Biobank (EBB) is a population-based biobank of the Estonian
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Genome Center at the University of Tartu. EBB contains almost 52,000 individuals of the Estonian 234 population (aged ≥18 years), which closely reflects the age, sex and geographical distribution of the 235 Estonian adult population [44] . At baseline, the general practitioners performed a standardized health 236 examination of the participants, who also donated blood samples for DNA, white blood cells and 237 plasma tests and filled out a questionnaire on health-related topics. All biobank participants have 238 consisted of a home interview and a health examination at the local health centre, or a condensed inter-279 view and health examination of non-respondents at home. In addition, several questionnaires were 280 used to assess symptoms, lifestyle, and exposures related to different health problems. Of the study 281 sample, 88% were interviewed, 80% attended a comprehensive health examination and 5% attended a 282 condensed examination at home [54] . Samples were excluded based on high contamination (>5%), high proportion of chimeric alignment 293 (>5%), low genotype quality (GQ < 50), low coverage (<20×), high coverage (> mean + 3 sd), 294 relatedness (identity-by-descent (IBD) > 0.1), sex mismatches, high genotype discordance (>5%) 295 between sequenced and chip-based data. Additionally, samples were filtered (mean ± 3 sd) based on 296 total number of variants, non-reference variants, singletons, heterozygous/homozygous variants ratio 297 (single nucleotide variants (SNVs) and indels were tested separately in the above-mentioned cases), 298 insertion/deletion ratio for novel indels, insertion/deletion ratio for indels observed in dbSNP, and 299 transition/transversion ratio. After filtering and exclusion of duplicates, the WGS datasets were 300 merged, containing 4,135 individuals (2,279 Estonians and 1,856 Finns). 301
The following variants were set to missing: GQ < 20, read depth > 200×, phred-scaled genotype 302 likelihood of reference allele < 20 for heterozygous and homozygous variant calls, and allele balance 303 <0.2 or >0.8 for heterozygous calls. The GATK Variant Quality Score Recalibration (VQSR) was 304 used to filter variants with a truth sensitivity of 99.8% for SNVs and of 99.9% for indels. Variants 305 with inbreeding coefficient < -0.3, quality by depth < 2 for SNVs and < 3 for indels, call rate < 90%, 306
and Hardy-Weinberg equilibrium (HWE) P value < 1×10 -9 were removed. Monomorphic, multi-allelic 307 variants, and low-complexity regions [58] were further excluded. The final IRP contains 38,226,084 308
variants. 309
Autosomal chromosomes and GRCh37 (hg19) human reference genome assembly was used for all 310
analysis. 311
Chip-based genotype data 312
The EBB participants have been analysed using Illumina genotyping arrays: 1) Global Screening 313 Array (GSA, N=33,277), 2) HumanCoreExome (CE, N=7,832), 3) HumanOmniExpress (OMNI, 314 N=8,137), and 4) 370K (N=2,640). Individuals with missing phenotype data were excluded. Final set 315 of genotyped data contained 48,163 unique individuals. The genotype calling for the microarrays was 316 performed using Illumina's GenomeStudio v2010.3 software. The genotype calls for rare variants on 317 the GSA array were corrected using the zCall software (version May 8th, 2012). After variant calling, 318 the data was filtered using PLINK v.1.90 [59] by sample (call rate > 95%, no sex mismatches between 319 phenotype and genotype data, heterozygosity < mean ± 3 sd) and marker-wise (HWE P value > 1 × 320
10
-6 , call rate > 95%, and for the GSA array additionally by Illumina GenomeStudio GenTrain score > 321 0.6, Cluster Separation Score > 0.4). Before the imputation, variants with MAF < 1% and C/G or T/A 322 polymorphisms as well as indels were removed, as these genotype calls do not allow precise phasing 323 and imputation. 324
Phasing and imputation
325
The WGS-based imputation reference panel was phased using Eagle v2.3 [60, 61] with default 326 parameters except the Kpbwt parameter that was set to 20000 to increase accuracy. Pre-phasing of 327 genotyped data was performed in similar manner for all four arrays separately with Eagle and imputed 328 with Beagle v4.1 [62] . All pre-phased genotype datasets were imputed twice using the following 329 (Fig 1) . 337
Phenotypes
338
In the association analysis, only unrelated individuals were included (IBD sharing < 0.2). Samples 339 were excluded by choosing the minimal list of related individuals to break all kinship ties and, if 340 possible, cases were preferred over controls using RELOUT5 tool from Allele 341 Table) . 351 
Single variants analysis
Fine-mapping 365
To identify causal variants that denote molecular mechanisms behind the associations, we performed 366 fine-mapping analysis using FINEMAP v1.3 [65] around (± 500 kilobase (kb)) genome-wide 367 significant loci detected by variant-wise analysis (Table 1) . FINEMAP was applied with default 368 parameters, allowing for at most five causal variants and the highest posterior probability for the 369 number of causal signals was used. 370 SKAT-O models were applied as used to discover 52 significant gene-trait associations in the 398 Estonian Biobank data ( Table 2) . S3 Table. Previously known associations for significant single variant analysis results. Relevant genome-wide associations from the GWAS Catalog for significant genomic regions (around genes (± 50 kb) with the lowest P value) detected by variant-wise analysis. Gray background refers to direct relationship between studied trait and GWAS Catalog entry. 
Enrichment analysis
S4
